A meta-analysis of negative symptoms in dual diagnosis schizophrenia

Psychological Medicine

Volumn 36, Issue 4, 2006, Pages 431-440

  Potvin, Stéphane ^a   Sepehry, Amir Ali ^a   Stip, Emmanuel ^a  

^a CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE DERIVATIVE; CANNABIS; COCAINE; DIAMORPHINE; PHENCYCLIDINE; PSYCHEDELIC AGENT;

AGE; ALCOHOLISM; CANNABIS ADDICTION; COCAINE DEPENDENCE; DRUG DEPENDENCE; EFFECT SIZE; HEROIN DEPENDENCE; HUMAN; MATHEMATICAL ANALYSIS; NEGATIVE SYNDROME; QUANTITATIVE ANALYSIS; RATING SCALE; REVIEW; SCHIZOPHRENIA; SEX; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW;

AFFECT; DEMOGRAPHY; DIAGNOSIS, DUAL (PSYCHIATRY); HUMANS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUBSTANCE-RELATED DISORDERS;

EID: 33644884247     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S003329170500574X     Document Type: Review

References (45)

1. Addington, J. & Addington, D. (1997). Substance abuse and cognitive functioning in schizophrenia. Journal of Psychiatry and Neuroscience 22, 99-104.
2. Allen, D. N., Goldstein, G., Forman, S. D., Keshavan, M. A., van Kammen, D. P. & Sanders, R. D. (2000). Neurologic examination abnormalities in schizophrenia with and without a history of alcoholism. Neuropsychiatry, Neuropsychology, and Behavioral Neurology 13, 184-187.
3. Andreasen, N. C. (1983). The Scale for the Assessment of Negative Symptoms. University of Iowa, Iowa City, IA.
4. Arndt, S., Tyrrell, G., Flaum, M. & Andreasen, N. C. (1992). Comorbidity of substance abuse and schizophrenia: The role of pre-morbid adjustment. Psychological Medicine 22, 379-388.
5. Bersani, G., Orlandi, V., Gherardelli, S. & Pancheri, P. (2002b). Cannabis and neurological soft signs in schizophrenia: Absence of relationship and influence on psychopathology. Psychopathology 35, 289-295.
6. Bersani, G., Orlandi, V., Kotzalidis, G. D. & Pancheri, P. (2002a). Cannabis and schizophrenia: Impact on onset, course, psychopathology and outcomes. European Archives of Psychiatry & Clinical Neuroscience 252, 86-92.
7. Blanchard, J. J., Brown, S. A., Horan, W. P. & Sherwood, A. R. (2000). Substance use disorders in schizophrenia: Review, integration, and a proposed model. Clinical Psychology Reviews 20, 207-234.
8. Borenstein, M. & Rothstein, H. (1999). Comprehensive Meta-Analysis: A Computer Program for Research Synthesis. Biostat: Englewood, NJ.
9. Buchanan, R. W. & Carpenter Jr., W. T. (1994). Domains of psychopathology and approach to the reduction of heterogeneity in schizophrenia. Journal of Nervous and Mental Disease 182, 193-204.
10. Bühler, B., Hambrecht, M., Löffler, W., an der Heiden, W. & Häfner, H. (2002). Precipitation and determination of the onset and course of schizophrenia by substance abuse - a retrospective and prospective study of 232 population-based first illness episodes. Schizophrenia Research 54, 243-251.
11. Compton, M. T., Fuman, A. C. & Kaslow, N. J. (2004). Lower negative symptom scores among cannabis-dependent patients with schizophrenia-spectrum disorders: Preliminary evidence from an African American first-episode sample. Schizophrenia Research 71, 61-64.
12. Conley, R. R., Kelly, D. L. & Gale, E. A. (1998). Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse. Schizophrenia Research 33, 95-101.
13. Cooper, H. & Hedges, L. V. (eds) (1994). The Handbook of Research Synthesis. Russell Sage Foundation: New York, NY.
14. DeQuardo, J. R., Carpenter, C. F. & Tandon, R. (1994). Patterns of substance abuse in schizophrenia: Nature and significance. Journal of Psychiatric Research 28, 262-275.
15. DerSimonian, R. & Laird, N. M. (1986). Meta-analysis in clinical trials. Controlled Clinical Trials 7, 177-188.
16. Devous, M. D., Trivedi, M. H. & Rush, A. J. (2001). Regional cerebral blood flow response to oral amphetamine challenge in healthy volunteers. Journal of Nuclear Medicine 156, 19-26.
17. Dixon, L., Haas, G., Weiden, P. J., Sweeney, J. & Frances, A. J. (1991). Drug abuse in schizophrenic patients: Clinical correlates and reasons for use. American Journal of Psychiatry 148, 224-230.
18. Drake, R. E., Osher, F. C. & Wallach, M. A. (1989). Alcohol use and abuse in schizophrenia: A prospective community study. Journal of Nervous & Mental Disease 177, 408-414.
19. Finlay, J. M. (2001). Mesoprefontal dopamine neurons and schizophrenia: the role of development abnormalities. Schizophrenia Bulletin 27, 431-442.
20. Gardner, E. L. (1997). Brain reward mechanisms. In Substance Abuse: A Comprehensive Textbook (3rd edn) (ed. J. H. Lowinson, P. Ruiz, R. B. Millman and J. G. Langrod), pp. 51-87. Williams & Wilkins: Baltimore.
21. Goswami, S., Matto, S. K., Basu, D. & Singh, G. (2004). Substance-abusing schizophrenics: Do they self-medicate? American Journal on Addictions 13, 139-150.
22. Grace, A. A. (1993). Cortical regulation of subcortical dopamine systems and its possible relevance to schizophrenia. Journal of Neural Transmission 91, 111-134.
23. Gut-Fayand, A., Dervaux, A., Olié, J. P., Lôo, H., Poirier, M. F. & Krebs, M. O. (2001). Substance abuse and suicidality in schizophrenia: a common risk factor linked to impulsivity. Psychiatry Research 102, 65-72.
24. Johnson, B. T. (1989). D-STAT: Software for the Meta-Analytic Review of Research Literatures. Hillsdale, New Jersey: Laurence Erlbaum.
25. Kay, S. R., Fiszbein, A. & Opler, L. A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261-276.
26. Khantzian, E. J. (1987). The self-medication hypothesis of addictive disorders: Focus on heroin and cocaine dependence. In The Cocaine Crisis (ed. D. Allen), pp. 65-74. Plenum Press: New York.
27. Kirkpatrick, B., Amador, X. F., Flaum, M., Yale, S. A., Gorman, J. M., Carpenter Jr., W. T., Tohen, M. & McGlashan, T. (1996). The deficit syndrome in the DSM-IV Field Trial: I. Alcohol and other drug abuse. Schizophrenia Research 20, 69-77.
28. Kovasznay, B., Fleischer, J., Tanenberg-Karant, M., Jandorf, L., Miller, A. D. & Bromet, E. (1997). Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophrenia Bulletin 23, 195-201.
29. Lysaker, P., Bell, M., Beam-Goulet, J. & Milstein, R. (1994). Relationship of positive and negative symptoms to cocaine abuse in schizophrenia. Journal of Nervous & Mental Disease 182, 109-112.
30. Mueser, K. T., Drake, R. E. & Wallach, M. A. (1998). Dual diagnosis: A review of etiological theories. Addictive Behaviors 23, 717-734.
31. Negrete, J. C. (2003). Clinical aspects of substance abuse in persons with schizophrenia. Canadian Journal of Psychiatry 48, 14-21.
32. Osher, F. C., Drake, R. E., Noordsy, D. L., Teague, G. B., Hurlbut, S. C., Biesanz, J. C. & Beaudett, M. S. (1994). Correlates and outcomes of alcohol use disorder among rural outpatients with schizophrenia. Journal of Clinical Psychiatry 55, 109-113.
33. Overall, J. E. & Gorham, D. R. (1962). Brief Psychiatric Rating Scale. Psychology Reports 10, 799-812.
34. Peralta, V. & Cuesta, M. J. (1992). Influence of cannabis abuse on schizophrenic psychopathology. Acta Psychiatrica Scandinavica 85, 127-130.
35. Potvin, S., Stip, E. & Roy, J. Y. (2003). Schizophrenia and addiction: an evaluation of the self-medication hypothesis. Encephale 29, 193-203.
36. Rabinowitz, J., Bromet, E. J., Lavelle, J., Carlson, G., Kovasznay, B. & Schwartz, J. E. (1998). Prevalence and severity of substance use disorders and onset of psychosis in first-admission psychotic patients. Psychological Medicine 28, 1411-1419.
37. Ries, R. K., Russo, J., Wingerson, D., Snowden, M., Comtois, K. A., Srebnik, D. & Roy-Byrne, P. (2000). Shorter hospital stays and more rapid improvement among patients with schizophrenia and substance disorders. Psychiatric Services 51, 210-215.
38. Salyers, M. P. & Mueser, K. T. (2001). Social functioning, psychopathology, and medication side effects in relation to substance use and abuse in schizophrenia. Schizophrenia Research 48, 109-123.
39. Serper, M. R., Alpert, M., Richarson, N. A., Dickson, S., Allen, M. H. & Werner, A. (1995). Clinical effects of recent cocaine use on patients with acute schizophrenia. American Journal of Psychiatry 152, 1464-1469.
40. Serper, M. R., Chou, J. C. Y., Allen, M. H., Czobor, P. & Cancro, R. (1999). Symptomatic overlap of cocaine intoxication and acute schizophrenia at emergency presentation. Schizophrenia Bulletin 25, 387-394.
41. Sevy, S., Robinson, D. G., Solloway, S., Alvir, J. M., Woerner, M. G., Bilder, R., Goldman, R., Lieberman, J. & Kane, J. (2001). Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder. Acta Psychiatrica Scandinavica 104, 367-374.
42. Swofford, C. D., Kasckow, J. W., Scheller-Gilkey, G. & Inderbitzin, L. B. (1996). Substance use: A powerful predictor of relapse in schizophrenia. Schizophrenia Research 20, 145-151.
43. Swofford, C. D., Scheller-Gilkey, G., Miller, A. H., Woolwine, B. & Mancer, R. (2000). Double jeopardy: Schizophrenia and substance use. American Journal of Drug & Alcohol Abuse 26, 343-353.
44. Volkow, N. D., Gillepsie, H., Mullani, N., Tancredi, L., Grant, C., Valentine, A. & Hollister, L. (1996). Brain glucose metabolism in chronic marijuana users at baseline and during marijuana intoxication. Psychiatry Research 67, 29-38.
45. Zisook, S., Heaton, R., Moranville, J., Kuck, J., Jernigan, T. & Braff, D. (1992). Past substance abuse and clinical course of schizophrenia. American Journal of Psychiatry 149, 552-553.